Ticker brief
OMER
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
11
authors 14d
10
crowd 14d
-1.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-14 → 2026-10-16 · now -0.29 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Briefingcom | B | -2.26 | 2 | -0.28 |
| @semodough | C | -1.06 | 1 | +0.20 |
| @Quantumup1 | C | +0.10 | 1 | +0.30 |
| @CHItrader | B | -0.22 | 1 | -0.50 |
| @zerohedge | C | -2.79 | 1 | +0.30 |
| @OpenOutcrier | C | · | 1 | -0.50 |
| @UTEX_io | C | +0.04 | 1 | -0.50 |
| @OzmosiHealth | C | · | 1 | -0.50 |
| @bullishchart | C | -1.21 | 1 | +0.10 |
| @Tickeron | C | +1.53 | 1 | -0.50 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @Tickeron | -0.50 | European regulators reaffirmed a negative opinion on narsoplimab. | · | tweet ↗ |
| 2026-10-16 | @bullishchart | +0.10 | Reports OMER submitting Yartemlea patient-level data to the CHMP for expert review. | · | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | -0.50 | CHMP issued a negative opinion after re-examining narsoplimab's European authorization application. | · | tweet ↗ |
| 2026-10-16 | @UTEX_io | -0.50 | Reports two upgrades plus regulatory and earnings developments across four stocks. | · | tweet ↗ |
| 2026-10-16 | @OpenOutcrier | -0.50 | Omeros suffered a European regulatory setback for narsoplimab. | · | tweet ↗ |
| 2026-10-16 | @zerohedge | +0.30 | Premarket roundup reports several analyst actions plus regulatory and earnings-related movers. | · | tweet ↗ |
| 2026-10-16 | @Briefingcom | -0.50 | CHMP reaffirmed its negative opinion on narsoplimab's European marketing application. | · | tweet ↗ |
| 2026-10-16 | @Briefingcom | -0.05 | Premarket gap list reports percentage moves for multiple stocks. | · | tweet ↗ |
| 2026-10-16 | @CHItrader | -0.50 | Omeros received a negative EU opinion for narsoplimab and its compassionate-use program ended. | · | tweet ↗ |
| 2026-10-14 | @Quantumup1 | +0.30 | Cantor reiterates Overweight and a $22 target while flagging a CHMP catalyst. | · | tweet ↗ |
| 2026-10-14 | @semodough | +0.20 | Cantor flags today's CHMP presentation and a possible final opinion by week-end as catalysts. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.